loader

aqn:mmed

LATEST ARTICLES
psychedelics investing

MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform

MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board
psychedelics investing

MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board

MindMed Announces Inclusion in FTSE Russell Indexes
psychedelics investing

MindMed Announces Inclusion in FTSE Russell Indexes

MindMed Increases Cash on Hand to CAD $205.2m , Closes Financing of CAD $19.5m
psychedelics investing

MindMed Increases Cash on Hand to CAD $205.2m , Closes Financing of CAD $19.5m

psychedelics investing

MindMed Announces C$19.5 Million Bought Deal Private Placement Offering

MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company
psychedelics investing

MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company

MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
psychedelics investing

MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company

MindMed's LSD Neutralizer Study Begins
psychedelics investing

MindMed's LSD Neutralizer Study Begins

MindMed's LSD Neutralizer Study Begins
psychedelics investing

MindMed's LSD Neutralizer Study Begins

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds
psychedelics investing

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics
psychedelics investing

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD
psychedelics investing

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

Latest News

More News

Outlook Reports

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES